LGT Fund Management Co Ltd. Has $674,000 Position in Stryker Co. (NYSE:SYK)

LGT Fund Management Co Ltd. increased its stake in Stryker Co. (NYSE:SYK) by 146.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,872 shares of the medical technology company’s stock after purchasing an additional 1,112 shares during the period. LGT Fund Management Co Ltd.’s holdings in Stryker were worth $674,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. LGT Group Foundation boosted its holdings in Stryker by 11.5% in the fourth quarter. LGT Group Foundation now owns 14,011 shares of the medical technology company’s stock valued at $5,045,000 after acquiring an additional 1,449 shares during the last quarter. Plato Investment Management Ltd lifted its position in Stryker by 1.1% during the 4th quarter. Plato Investment Management Ltd now owns 12,295 shares of the medical technology company’s stock valued at $4,443,000 after purchasing an additional 131 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Stryker in the 4th quarter valued at about $181,000. Jones Financial Companies Lllp grew its position in shares of Stryker by 44.4% during the 4th quarter. Jones Financial Companies Lllp now owns 27,291 shares of the medical technology company’s stock worth $9,826,000 after buying an additional 8,397 shares during the period. Finally, Modera Wealth Management LLC raised its stake in shares of Stryker by 5.6% during the fourth quarter. Modera Wealth Management LLC now owns 45,132 shares of the medical technology company’s stock worth $16,250,000 after buying an additional 2,387 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $394.53 on Tuesday. The stock has a market cap of $150.54 billion, a PE ratio of 50.84, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The stock has a 50-day moving average price of $381.06 and a two-hundred day moving average price of $371.92. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Equities analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.85%. Stryker’s dividend payout ratio is 43.30%.

Analyst Ratings Changes

SYK has been the subject of a number of analyst reports. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Citigroup restated a “buy” rating and set a $450.00 target price on shares of Stryker in a research report on Wednesday, February 26th. Finally, Barclays increased their price target on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.